Cdc7-IN-20

Cat. No.: HY-163374

Molecular Formula: $C_{15}H_{16}N_4OS$

Molecular Weight: 300.38

Target: CDK

Pathway: Cell Cycle/DNA Damage

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Cdc7-IN-20 (EP-05) is an orally effective and selective Cdc7 inhibitor with IC_{50} and K_i values of 0.93 and 0.11 nM, respectively. Cdc7-IN-20 has antitumor activity[1].

In Vitro

Cdc7-IN-20 (0.5, 1, 2 μM, 24 h) can inhibit the proliferation of COLO 205 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	COLO 205
Concentration:	0.5, 1, 2 μM
Incubation Time:	24 h
Result:	Inhibited the phosphorylation at Ser53 and Ser40 of MCM2 in a dose-dependent manner.

In Vivo

Cdc7-IN-20 (2, 4, 8 mg/kg, orally, for 3 consecutive days) has an antitumor effect in COLO 205 xenograft mouse model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	COLO 205 xenograft mice model[1]
Dosage:	2, 4, 8 mg/kg
Administration:	p.o. for 3 consecutive days
Result:	Inhibit the expression of p-MCM2 protein.

REFERENCES

[1]. Fu M, et al. Discovery of a potent and selective cell division cycle 7 inhibitor from 6-(3-fluoropyridin-4-yl) thieno [3, 2-d] pyrimidin-4 (3H)-one derivatives as an orally active antitumor agent. Acta Pharmaceutica Sinica. B, 2024, 14(2): 893.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA